WO2002055742A3 - Rapid method for screening compounds for in vivo activity - Google Patents

Rapid method for screening compounds for in vivo activity Download PDF

Info

Publication number
WO2002055742A3
WO2002055742A3 PCT/EP2002/000106 EP0200106W WO02055742A3 WO 2002055742 A3 WO2002055742 A3 WO 2002055742A3 EP 0200106 W EP0200106 W EP 0200106W WO 02055742 A3 WO02055742 A3 WO 02055742A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
active compound
rapid method
potentially
encapsulation device
Prior art date
Application number
PCT/EP2002/000106
Other languages
French (fr)
Other versions
WO2002055742A2 (en
Inventor
Piotr Lassota
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Piotr Lassota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Piotr Lassota filed Critical Novartis Ag
Priority to EP02703539A priority Critical patent/EP1364206A2/en
Priority to JP2002556788A priority patent/JP2004517334A/en
Priority to AU2002237261A priority patent/AU2002237261A1/en
Priority to US10/250,739 priority patent/US20040067540A1/en
Publication of WO2002055742A2 publication Critical patent/WO2002055742A2/en
Publication of WO2002055742A3 publication Critical patent/WO2002055742A3/en
Priority to US11/643,248 priority patent/US20070105147A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Abstract

The present invention provides a rapid method for screening potentially pharmaceutically useful compounds for activity in vivo. The method has the steps of growing a target cell into which a reporter gene was introduced in a biocompatible, semipermeable encapsulation device; implanting the semi-permeable encapsulation device into a subject; administering a potentially pharmaceutically active compound to said subject; removing said encapsulation device from said subject after in vivo exposure to the potentially pharmaceutically active compound and evaluating said target cell for reaction to said potentially paharmaceutically active compound by measuring the expression of said reporter gene.
PCT/EP2002/000106 2001-01-09 2002-01-08 Rapid method for screening compounds for in vivo activity WO2002055742A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02703539A EP1364206A2 (en) 2001-01-09 2002-01-08 Rapid method for screening compounds for in vivo activity
JP2002556788A JP2004517334A (en) 2001-01-09 2002-01-08 Rapid method for screening in vivo activity of compounds
AU2002237261A AU2002237261A1 (en) 2001-01-09 2002-01-08 Rapid method for screening compounds for in vivo activity
US10/250,739 US20040067540A1 (en) 2001-01-09 2002-01-08 Rapid method for screening compounds for in vivo activity
US11/643,248 US20070105147A1 (en) 2001-01-09 2006-12-21 Rapid method for screening compounds for in vivo activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26057101P 2001-01-09 2001-01-09
US60/260,571 2001-01-09
US30261401P 2001-07-02 2001-07-02
US60/302,614 2001-07-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/643,248 Continuation US20070105147A1 (en) 2001-01-09 2006-12-21 Rapid method for screening compounds for in vivo activity

Publications (2)

Publication Number Publication Date
WO2002055742A2 WO2002055742A2 (en) 2002-07-18
WO2002055742A3 true WO2002055742A3 (en) 2003-09-04

Family

ID=26948073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000106 WO2002055742A2 (en) 2001-01-09 2002-01-08 Rapid method for screening compounds for in vivo activity

Country Status (5)

Country Link
US (2) US20040067540A1 (en)
EP (1) EP1364206A2 (en)
JP (1) JP2004517334A (en)
AU (1) AU2002237261A1 (en)
WO (1) WO2002055742A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104388538A (en) * 2014-11-18 2015-03-04 中国人民解放军第三军医大学 Method for screening histone deacetylase inhibitor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553948B1 (en) * 2002-09-13 2011-08-24 Virginia Commonwealth University Combination of imatnib and a histone deacetylase inhibitor for the treatment of leukemia
WO2004078984A1 (en) 2003-03-05 2004-09-16 Janssen Pharmaceutica N.V. Animal model for the fast identification of pharmaceutical active compounds in vivo
WO2004106924A2 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
WO2006071903A2 (en) * 2004-12-28 2006-07-06 Ptc Therapeutics, Inc. Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions
CA2653657C (en) 2006-06-12 2015-10-27 Novartis Ag Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
SG11201501039WA (en) * 2012-09-06 2015-03-30 Univ Nanyang Tech Hyaluronic acid-based drug delivery systems
CN107976534A (en) * 2016-10-21 2018-05-01 上海立迪生物技术股份有限公司 A kind of quick drug effect screening technique of antitumor drug and its special purpose device
EP3840693A1 (en) * 2018-08-22 2021-06-30 Boston Scientific Scimed Inc. Cell encapsulation device including a porous tube

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218400A1 (en) * 1985-09-18 1987-04-15 Damon Biotech, Inc. Assay methods for chemotherapeutic agents
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
WO1994025074A1 (en) * 1993-05-05 1994-11-10 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of evaluating chemotherapeutic agents in vivo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE428379B (en) * 1978-05-31 1983-06-27 Lkb Produkter Ab DETERMINATION OF ATOL AND REAGENTS OF BIOLUMINISM
US5744310A (en) * 1996-07-29 1998-04-28 The Burnham Institute Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218400A1 (en) * 1985-09-18 1987-04-15 Damon Biotech, Inc. Assay methods for chemotherapeutic agents
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
WO1994025074A1 (en) * 1993-05-05 1994-11-10 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of evaluating chemotherapeutic agents in vivo

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASCIARI JOSEPH J ET AL: "Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 86, no. 24, 1994, pages 1846 - 1852, XP009009925, ISSN: 0027-8874 *
HOLLINGSHEAD M ET AL: "The hollow fiber assay.", 1999, CONTRIBUTIONS TO ONCOLOGY, VOL. 54, PAGE(S) 109-120, DRUG DEVELOPMENT. 1999 S. KARGER GMBH POSTFACH, D-79095, FREIBURG, GERMANY, ISBN: 3-8055-6786-3, XP009009927 *
HOLLINGSHEAD MELINDA ET AL: "In vivo drug screening applications of HIV-infected cells cultivated within hollow fibres in two physiologic compartments of mice.", ANTIVIRAL RESEARCH, vol. 28, no. 3, 1995, pages 265 - 279, XP002239733, ISSN: 0166-3542 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104388538A (en) * 2014-11-18 2015-03-04 中国人民解放军第三军医大学 Method for screening histone deacetylase inhibitor
CN104388538B (en) * 2014-11-18 2017-01-18 中国人民解放军第三军医大学 Method for screening histone deacetylase inhibitor

Also Published As

Publication number Publication date
WO2002055742A2 (en) 2002-07-18
US20040067540A1 (en) 2004-04-08
US20070105147A1 (en) 2007-05-10
JP2004517334A (en) 2004-06-10
AU2002237261A1 (en) 2002-07-24
EP1364206A2 (en) 2003-11-26

Similar Documents

Publication Publication Date Title
BRPI0415288A (en) compound, pharmaceutical composition, method for treating or preventing disease, and method for preparing the compound
EP2386204A3 (en) Plant disease controlling composition and method for controlling plant disease
WO2002081453A8 (en) Thiohydantoins and use thereof for treating diabetes
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
WO2002055742A3 (en) Rapid method for screening compounds for in vivo activity
AU2003292061A1 (en) Method for producing an immediately decomposing oral form of administration which releases active ingredients
WO2009149224A3 (en) Elastase treatment of tissue matrices
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
PT1206467E (en) N-HETEROCYCLIC DERIVATIVES AS US INHIBITORS
WO2004076657A3 (en) Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
AU2003298060A1 (en) Abutment for a dental implant, dental implant comprising such an abutment, and method for the production of dentures by means of said dental implant
FR2850099B1 (en) IM-9 CRYSTALLIZED SOLID AND PROCESS FOR PREPARING THE SAME
WO2005105768A3 (en) Process for preparation of mycophenolic acid and ester derivatives thereof
WO2006061715A3 (en) Methylene inhibitors of matrix metalloproteinase
NO20041059L (en) Combination of selected opioids with muscarinic antagonists for the treatment of urinary incontinence
ATE394379T1 (en) 4-ALKOXY-CYCLOHEXANE-1-AMINO-CARBONIC ACID ESTERS AND METHOD FOR THE PRODUCTION THEREOF
AU2003298945A1 (en) Method of preparing biologically active formulations
WO2004080337A3 (en) Lip implant and method for insertion
EP1801232A4 (en) Method of screening transmembrane enzyme inhibitory substance
WO2002072567A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE50208851D1 (en) GELIER SUGAR AND METHOD FOR THE PRODUCTION THEREOF
AU2002325614A1 (en) Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
WO2005056563A3 (en) Process for the preparation of thiazolopyrimidines
ZA200603236B (en) Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002703539

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002556788

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10250739

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002703539

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002703539

Country of ref document: EP